InfoBionic develops the MoMe® ARC platform, a third-generation virtual telemetry system for remote, wireless monitoring and diagnosis of cardiac arrhythmias. Its MoMe® ARC 4-in-1 monitor pairs a 3rd-generation remote ECG device with a Bluetooth diagnostic 6-lead sensor and offers both patch-type and wire-based sensors. The system delivers heartbeat-to-heartbeat, full-disclosure ECG data over the cloud to provide near real-time, hospital telemetry-level access for clinicians. The company recently received FDA approval for the third-generation MoMe® ARC platform. InfoBionic plans to use the Series D proceeds to continue commercial expansion of the MoMe® ARC system. The company is led by CEO Stuart Long. InfoBionic develops the MoMe® Kardia remote cardiac monitoring platform that provides physicians 24/7 on-demand access to full-disclosure Holter, Event, and MCT data via a HIPAA-compliant portal. The system is positioned to replicate in-hospital telemetry data in the outpatient setting and was granted FDA 510(k) clearance in 2015. The company targets an addressable U.S. market estimated at $1.4 billion and recently announced a commercial distribution partnership to enhance market penetration. InfoBionic reports month-to-month subscription growth rates exceeding 35% since this time last year. The completed financing is intended to support continued commercial expansion of the MoMe® Kardia system. InfoBionic develops the MoMe® Kardia system, a cloud-based remote patient monitoring platform for cardiac arrhythmia detection. The platform streams continuous electrocardiogram, respiration and motion data to the cloud for analysis and delivers automated reporting to mobile devices, tablets and web portals. It provides on-demand, actionable monitoring data and analytics for Holter, Event and mobile cardiac telemetry (MCT) directly to physicians. The company is led by Nancy Briefs, President, CEO and Co-Founder. InfoBionic raised a financing round to support commercialization of the MoMe® Kardia system. The articles report the company is based in Lowell, Massachusetts. InfoBionic is an emerging digital health company focused on providing anywhere, anytime access to cardiac event monitoring with improved event detection and clinical efficacy through a lower-cost business model. Its lead product, the MoMe System, is a cloud-based, multi-pass analysis universal remote patient monitoring platform that provides seamless transition between Holter, Event, and Mobile Cardiac Telemetry monitoring modes in one device. MoMe Kardia is positioned to address the roughly $3B worldwide cardiac monitoring market by delivering enhanced analytics and on-demand access to patient data for diagnosis. Proceeds from the recently closed Series B tranche will enable commercialization of the MoMe System in Europe and the United States. The company emphasizes cloud technology to improve patient monitoring, diagnosis and treatment while reducing operating and healthcare costs. Safeguard Scientifics’ participation and board representation signal strategic support for commercialization and growth.

Total raised

$75M

Funding rounds

4

Latest round

Equity

Latest activity

Sep 2018